symbolic image
Meril Life Sciences launched its Myval OctaPro transcatheter heart valve (THV) at GISE 2024 and PCR London Valve 2024. This is such a technology that heart treatment can now be performed without open heart surgery. This has been made possible with the Myval Transcatheter Heart Valve (THV) device from Merrill Life Sciences.
Dr. Ashok Seth of Fortis Escorts Heart Institute and Dr. Rajneesh Kapoor of Medanta emphasized the importance of these innovations in improving patient outcomes. According to the report, Myval OctaPro THV features less frame foreshortening for precise deployment and a sizing matrix that includes conventional, intermediate and extra-large options to accommodate different patient anatomies.
Merrill presented results from the LANDMARK trial and the COMPARE-TAV trial at PCR London Valve 2024. “We are proud to collaborate with physicians around the world to advance TAVR technology and improve patient outcomes through innovation,” said Sanjeev Bhatt, senior vice president of corporate strategy at Merrill Life Sciences.
What is OctaPro THV?
The next-generation OctaPro THV expandable balloon valve features minimal foreshortening, ensuring precise deployment and alignment. Additionally, nine valve sizes (including intermediate and extra-large sizes) allow the correct valve size to be selected based on the patient’s body structure.
